Sugi Predict

Sugi Predict / Compounds / SCHEMBL2583638

SCHEMBL2583638

SCHEMBL2583638

CC(C)(C)c1cccc(NC(=O)C2CCCNC2c2ccccc2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXFP1 Q9HBX9 5/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ TACR1 P25103 4/20 0.44
▸ GRK2 P25098 1/20 0.42
▸ CASP6 P55212 1/20 0.42
▸ CASP8 Q14790 1/20 0.42
▸ CTDSP1 Q9GZU7 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ APEX1 P27695 1/20 0.42
▸ HDAC3 O15379 1/20 0.41
▸ HDAC8 Q9BY41 1/20 0.41
▸ HDAC6 Q9UBN7 1/20 0.41
▸ KCNK9 Q9NPC2 1/20 0.40
▸ KCNJ6 P48051 1/20 0.40
▸ KCNJ5 P48544 1/20 0.40
▸ KCNJ3 P48549 1/20 0.40
▸ MAPT P10636 2/20 0.39
▸ GAA P10253 2/20 0.39
▸ TP53 P04637 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12160763 1.00 RXFP1 (0.49) RXFP1SMN1; SMN2TACR1GRK2CASP6
SCHEMBL16280645 1.00 RXFP1 (0.49) RXFP1SMN1; SMN2TACR1GRK2CASP6
SCHEMBL29726766 0.90 RXFP1 (0.44) RXFP1SMN1; SMN2GRK2CASP6CASP8
SCHEMBL16280642 0.90 RXFP1 (0.44) RXFP1SMN1; SMN2GRK2CASP6CASP8
SCHEMBL2567672 0.90 RXFP1 (0.44) RXFP1SMN1; SMN2GRK2CASP6CASP8
SCHEMBL20426001 0.90 RXFP1 (0.44) RXFP1SMN1; SMN2GRK2CASP6CASP8
SCHEMBL12160774 0.90 RXFP1 (0.44) RXFP1SMN1; SMN2GRK2CASP6CASP8
SCHEMBL29726747 0.81 RXFP1 (0.50) RXFP1SMN1; SMN2GRK2CASP6CASP8
SCHEMBL18801716 0.81 RXFP1 (0.50) RXFP1SMN1; SMN2GRK2CASP6CASP8
SCHEMBL12160788 0.81 RXFP1 (0.50) RXFP1SMN1; SMN2GRK2CASP6CASP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230102258-A1 C5AR ANTAGONISTS CHEMOCENTRYX, INC. 2023-03-30 — — US disclosed
EP-4015504-A1 C5AR ANTAGONISTS ChemoCentryx, Inc. (US) 2022-06-22 — — EP disclosed
EP-3508477-B1 C5AR ANTAGONISTS CHEMOCENTRYX INC (US) 2021-11-10 — — EP disclosed
US-10660897-B2 C5aR antagonists CHEMOCENTRYX, INC. (US) 2020-05-26 — — US disclosed
EP-3508477-A1 C5AR ANTAGONISTS ChemoCentryx, Inc. (US) 2019-07-10 — — EP disclosed
EP-3078658-B1 C5AR ANTAGONISTS CHEMOCENTRYX INC (US) 2019-04-10 — — EP disclosed
US-10035768-B2 C5aR antagonists CHEMOCENTRYX, INC. (US) 2018-07-31 — — US disclosed
US-20180179160-A1 C5AR ANTAGONISTS CHEMOCENTRYX, INC. 2018-06-28 — — US disclosed
EP-2585064-B1 C5AR ANTAGONISTS CHEMOCENTRYX INC (US) 2017-05-03 — — EP disclosed
US-20170114017-A1 C5AR ANTAGONISTS CHEMOCENTRYX, INC. 2017-04-27 — — US disclosed
US-20130317028-A1 C5aR ANTAGONISTS CHEMOCENTRYX, INC. (US) 2013-11-28 — — US disclosed
US-20130172347-A1 C5AR ANTAGONISTS CHEMOCENTRYX, INC. 2013-07-04 — — US disclosed
US-8445515-B2 C5aR antagonists CHEMOCENTRYX, INC. (US) 2013-05-21 — — US disclosed
EP-2585064-A1 C5AR ANTAGONISTS ChemoCentryx, Inc. (US) 2013-05-01 — — EP disclosed
CN-103068385-A C5ar antagonists CHEMOCENTRYX INC 2013-04-24 — — CN disclosed
WO-2011163640-A1 C5AR ANTAGONISTS CHEMOCENTRYX, INC. (US) 2011-12-29 — — WO disclosed
CN-102264227-A C5ar antagonists — 2011-11-30 — — CN disclosed
US-20110275639-A1 C5aR ANTAGONISTS CHEMOCENTRYX, INC. (US) 2011-11-10 — — US disclosed
US-20100311753-A1 C5aR ANTAGONISTS CHEMOCENTRYX, INC. (US) 2010-12-09 — — US disclosed
US-20100160320-A1 C5aR ANTAGONISTS CHEMOCENTRYX, INC. (US) 2010-06-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160320-A1 C5aR ANTAGONISTS C5AR1, C5AR2, C3AR1 RXFP1 911/4885SMN1; SMN2 2376/4885TACR1 97/4885
US-10660897-B2 C5aR antagonists C5AR1, C5AR2, C3AR1 RXFP1 911/4885SMN1; SMN2 2376/4885TACR1 97/4885
US-20110275639-A1 C5aR ANTAGONISTS C5AR1, C5AR2, C3AR1 RXFP1 911/4885SMN1; SMN2 2376/4885TACR1 97/4885
US-20170114017-A1 C5AR ANTAGONISTS C5AR1, C5AR2, C3AR1 RXFP1 911/4885SMN1; SMN2 2376/4885TACR1 97/4885
US-20180179160-A1 C5AR ANTAGONISTS C5AR1, C5AR2, C3AR1 RXFP1 911/4885SMN1; SMN2 2376/4885TACR1 97/4885
US-10035768-B2 C5aR antagonists C5AR1, C5AR2, C3AR1 RXFP1 911/4885SMN1; SMN2 2376/4885TACR1 97/4885
US-20130317028-A1 C5aR ANTAGONISTS C5AR1, C5AR2, C3AR1 RXFP1 911/4885SMN1; SMN2 2376/4885TACR1 97/4885
US-20230102258-A1 C5AR ANTAGONISTS C5AR1, C5AR2, C3AR1 RXFP1 911/4885SMN1; SMN2 2376/4885TACR1 97/4885
US-20100311753-A1 C5aR ANTAGONISTS C5AR1, C5AR2, C3AR1 RXFP1 911/4885SMN1; SMN2 2376/4885TACR1 97/4885
US-20130172347-A1 C5AR ANTAGONISTS C5AR1, C5AR2, C3AR1 RXFP1 911/4885SMN1; SMN2 2376/4885TACR1 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.